SABCS 2025 | ECOG-ACRIN EA1131: post-NACT TILs and intrinsic subtype in residual TNBC

Sunil Badve • 12 Dec 2025

SABCS 2025

Breast Cancer

EA1131

Sunil Badve, MD, FRCPath, Emory School of Medicine, Atlanta, GA, comments on the secondary analysis of the ECOG-ACRIN EA1131 trial (NCT02445391) examining stromal tumor-infiltrating lymphocytes (TILs) and intrinsic subtype in patients with residual triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT). The analysis shows that low TIL levels combined with a basal-like subtype identify a particularly high-risk group with significantly worse invasive disease-free survival. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2025 Meeting in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.